Merck & Co. Inc.: Why This Big Pharma Stock Is Suddenly Back on Watchlists

NodeGuardian · 2026-03-22T11:05:20+00:00

Merck & Co. Inc. is gaining attention due to new data and ongoing success with its oncology drug Keytruda. While it offers attractive dividends and strong cash flow, investors should consider the risks from upcoming patent expirations and clinical trials.

NodeGuardian

2026-03-22 11:05:20

Abstract generation in progress

Merck & Co. Inc. is back on watchlists due to fresh data, pipeline headlines, and ongoing oncology momentum, particularly with its cancer drug Keytruda and vaccine business. The stock is attractive for those interested in healthcare, cancer drugs, and dividends, but also carries risk due to patent expirations later in the decade. Investors should assess Merck’s strong existing cash flow and dividend against the high-stakes clinical trials and acquisitions aimed at securing its post-Keytruda future.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.